## **Supplementary Materials:**

Figures S1 – S10



Supplementary Figure 1

Supplementary Figure 1. Assessment of uterine *Ct* burden in immunized mice.

Representative micrographs of McCoy cells stained with Evans blue (red) incubated with titrated tissue homogenates of uteri harvested on day 5 after *Ct* challenge to detect inclusion forming units (IFUs) of *Ct*. IFUs were identified by staining with anti-MOMP mAb (green). Original magnification 40X. Quantitative data are provided in **Fig. 2C**.



Supplementary Figure 2. Protection against Chlamydia serovar E. Ct burden

following i.u. challenge with live Ct-E 4 weeks after immunization with Ct-E or UV-Ct-

E-cSAP. n = 3 mice/group; broken line indicates limit of detection; \*\*\* P<0.001.



Supplementary Figure 3. *Ct*-specific antibodies and uterine CD8 T cells after UV-*Ct*cSAP immunization. (A) Anti-*Ct* IgG titers in serum were determined by enzyme-linked immunosorbent assay 4 weeks after immunization. Symbols represent optical densities (OD) of sera from individual mice. Results were pooled from two independent experiments. \*\*\**P*<0.001. ND, not detected; LOD, limit of detection. (B) Frequency of CD8 T cells in the uterus 4 days after immunization (n = 4-6 mice/group; \**P*<0.05; \*\*\**P*<0.001). Error bars show mean ± SEM.



Supplementary Figure 4. Immunized RAG-2<sup>-/-</sup> mice do not develop immunity or tolerance against *Ct* challenge. *Ct* burden following i.u. challenge with live *Ct* 4 weeks after immunization of RAG-2<sup>-/-</sup> mice (n= 5 mice/group; \*\*\* P<0.001).



Supplementary Figure 5. Phenotype of NR1  $T_N$  cells. (A) Gating strategy to identify TCR transgenic (i.e. CD4<sup>+</sup>V $\beta$ 8.3<sup>+</sup>V $\alpha$ 2<sup>+</sup>) T cells among splenic and LN mononuclear cells from NR1 mice. (B) Representative dot plots of CD4<sup>+</sup>V $\beta$ 8.3<sup>+</sup>V $\alpha$ 2<sup>+</sup> NR1 cells stained for differentiation and activation markers indicate a predominant CD62L<sup>+</sup> CD44<sup>low</sup> CXCR3<sup>-</sup> KLRG1<sup>-</sup> phenotype characteristic of T<sub>N</sub>.



Supplementary Figure 6. Composition of Ag-presenting cells in uteri of naïve and

immunized mice. (A) Gating strategy for MHC class II<sup>+</sup> uterine APC subsets. (B)

Representative histogram plots of CD11c, CD11b and CX3CR1 expression on CD45<sup>+</sup> MHC-II<sup>+</sup> uterine APC subsets in naïve mice. (**C**) Total number of uterine APCs and (**D**) relative distribution of APC subsets 18 hours after immunization, the timepoint at which APC subsets were harvested for experiments in **Fig. 5B** and **D-F**. (n=5 mice/group). (**E**) Representative histogram plots of costimulatory molecule and cytokine expression on CD103<sup>+</sup> and CD103<sup>-</sup> uterine DC subsets following immunization with *Ct* (green), UV-*Ct* (red) or UV-*Ct*-cSAP (blue). Error bars show mean  $\pm$  SEM.



Supplementary Figure 7. Long-term protection of mice after i.n. UV-*Ct*-cSAP immunization. *Ct* burden was determined by qPCR following i.u. *Ct* challenge 6 months after s.c. or i.n. immunization as shown in **Fig. 1A** (n = 5-6 mice/group; \*\*\**P*<0.001). ns, non significant.



B i.n.





**Supplementary Figure 8.** Accumulation of *Ct*-specific T cells in blood and uterus after s.c., i.n. or i.u. immunization with UV-*Ct*-cSAP. (A) Representative FACS plots of uterus resident T cells 30 days after immunization. (B) Representative confocal micrographs of uterine mucosa stained with anti-CD326 (epithelial cells, green), anti-CD90.1 (transgenic marker for NR1 cells, red) and anti-CD31 (endothelial cells, grey) 30 days after intranasal or (C) intrauterine immunization. *cav*, uterine cavity. Scale bar: 70 μm. Original magnification 400X.



Supplementary Figure 9. Effect of anti- $\alpha$ 4 MAb treatment on bulk CD4 T cells and NR1 cells in spleen and uterus. (A-C) T cell numbers were quantified by flow cytometry in single-cell suspensions of tissues from experimental groups 1, 2 and 3 described in Fig. 6E (n = 5 mice per group, \*\*\**P*<0.001). Total number of CD4<sup>+</sup> T cells in (A) spleen and (B) uterus. (C) Total number of splenic NR1 cells. (D) The proliferation rate of uterine NR1 T<sub>RM</sub> cells in groups 1 and 3 was determined after *Ct* challenge using FACS to assess BrDU uptake or Ki-67 staining to detect actively dividing cells (n=4 mice/group). Error bars show mean ± SEM.



**Supplementary Figure 10. Timecourse of blood chimerism of circulating CD4<sup>+</sup> T cells in parabiotic mice.** Chimerism was determined by flow cytometry during days 3-6 after parabiosis surgery.